Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00391716 · ClinicalTrials.gov registry record · Phase 2
Gabapentin Treatment of Alcohol Dependence
A Phase 2 study of Alcoholism and Alcohol Dependence, sponsored by The Scripps Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00391716: Completed Phase 2 study of Alcoholism and Alcohol Dependence, sponsored by The Scripps Research Institute.
NCT00391716 is a Phase 2 study of Alcoholism and Alcohol Dependence that has completed, run by The Scripps Research Institute. The registered enrollment target is 150 participants, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00391716, a Phase 2 study of Alcoholism and Alcohol Dependence, has completed, sponsored by The Scripps Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Gabapentin treatment for alcohol dependence
Primary Outcome
Rate of complete abstinence was defined as the number of participants who drank no alcohol during 12 weeks of treatment, where the denominator is the intent to treat population. Rate of heavy drinking abstinence is defined as no heavy drinking days while on study (4 or more for women, 5 or more for men).
Conditions Studied
Interventions
- DRUG placebo
- DRUG Gabapentin 900mg
- BEHAVIORAL behavioral counseling
- DRUG gabapentin 1800mg
Study Locations (1)
California
- The Scripps Research Institute - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-02 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
What the finished NCT00391716 record still lists
NCT00391716 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Alcoholism appearing as the primary indexed condition, and to 4 interventions - of which placebo is the first listed.
NCT00391716 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00391716 about?
NCT00391716 is a clinical study titled "Gabapentin Treatment of Alcohol Dependence". Gabapentin treatment for alcohol dependence
What is the current status of trial NCT00391716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2004-02. Estimated completion is 2010-02.
What conditions does trial NCT00391716 study?
This clinical trial studies the following conditions: Alcoholism, Alcohol Dependence.
What interventions are being tested in trial NCT00391716?
The interventions under investigation include: placebo (DRUG), Gabapentin 900mg (DRUG), behavioral counseling (BEHAVIORAL), gabapentin 1800mg (DRUG).
Who is sponsoring clinical trial NCT00391716?
This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00391716 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00391716's enrollment target sits among peer trials
150 27th of 65 higher than 39 of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine Alcohol (in Treatment-Resistant Depression)
RECRUITING · Phase 2
-
Ibudilast for Treating Alcohol Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
A Study of LY2940094 in Participants With Alcohol Dependency
COMPLETED · Phase 2
-
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
-
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia